Counterparties stepping up before the numbers do: escalating committed demand the reported results don't yet show
The model's full reasoning — Q2 2022 call → NOWe need to determine if management describes counterparties stepping up their commitment beyond prior levels, and that reported results don't yet reflect that step-up because it's only beginning. Looking at the transcript: The call is about disappointing results, with challenges in Medicare Advantage. They discuss a strategic review, resetting growth, and population health initiatives like SelectRx. They mention progress in SelectRx: "we have completed over 40,000 gross customer enrollments" and "over 10,000 active paying members" and "we remain confident with our forecast to exit this fiscal year with around 25,000 active paying SelectRx members, over 10x what we started the year with." That indicates growth in that business. But is that a step-up by paying counterparties? The customers are enrolling in SelectRx, but the revenue from that is not yet significant. However, the question is about counterparties who pay the company—customers, clients, partners, etc. The SelectRx members are paying customers? They are active paying members. But the escalation is in membership numbers, not necessarily a commitment from a few large counterparties. The question asks about "counterparties moving to a distinctly higher level of engagement than they had before" - this could be the growth in SelectRx members. But is that described as a step-up that is already happening and that the reported results don't yet reflect? They say "we are more excited than ever about the high level of consumer interest in and demand for the pharmacy services we offer." And they note that there is a lag between enrollment and first shipment, and then falloff. They say "we have learned the nuances of this business and made many operational improvements to lower falloff and speed up the onboarding process. You can see those efforts starting to take shape on the right-hand chart, which shows the growth in our paying membership." So they are seeing growth in paying members, but the revenue from that is still small relative to the overall business. However, the question is specifically about counterparties stepping up their commitment. The SelectRx members are individual consumers, not necessarily "counterparties" in the sense of large partners. The call also mentions carrier partners, but they are not described as stepping up. The main narrative is about challenges and resetting.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
KOP · Q2 2018 → YESThe question is: Does management describe that counterparties (customers etc.) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that reported results do not yet meaningfully reflect...**NO** The transcript does not describe any counterparties (customers, clients, partners, etc.) currently stepping up their commitment to a distinctly higher level of engagement beyond prior patterns in a way that is already occurring or committed now, with the reported results lagging because most of the benefit is still ahead. The closest item is the major box store converting its ground-contact treated wood program to Koppers’ patented MicroPro technology, planned for late fall with “little effect on the balance of 2018” and a “nice boost heading into 2019.
SCPH · Q3 2023 → YESThe question is: Does management describe that counterparties who pay the company are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully ...YES The transcript shows management describing a clear escalation in payer commitments: a new unrestricted-access agreement with the largest closed IDN (over 8 million lives, fixed copay) and preferred formulary status with a major government retiree payer (adding 1.1 million lives). They explicitly note that direct IDN purchases were not meaningful in Q3 but will be “a meaningful part of our business” moving forward, especially in 2024, and that the new payer decisions “could positively impact FUROSCIX co-pays as early as the fourth quarter.
GFS · Q3 2021 → YESThe question is: Does management describe that counterparties (customers) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully reflect ...**YES** Management describes counterparties (customers) stepping up their commitment through new and expanded long-term agreements (LTAs) and prepayments/access fees, which have grown since the roadshow (from ~$2.5B to north of $3B, with additional $500M+ added post-roadshow) and now exceed $20B in forward revenues. This is framed as real escalation in committed business, with customers signing more agreements and prepaying for future capacity. The reported Q3 results ($1.7B revenue, $0.07 adjusted EPS) and Q4 guidance ($1.